c-Myc-Targeting PROTAC Based on a TNA-DNA Bivalent Binder for Combination Therapy of Triple-Negative Breast Cancer

Cancer statistics, 2022

(2022) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

PROTAC targeted protein degraders: the past is prologue

(2022) Miklós Békés et al.   NATURE REVIEWS DRUG DISCOVERY

A Nanoparticle’s Journey to the Tumor: Strategies to Overcome First-Pass Metabolism and Their Limitations

(2022) Joshua J. Milligan et al.   Cancers

MYC inhibition reprograms tumor immune microenvironment by recruiting T lymphocytes and activating the CD40/CD40L system in osteosarcoma

(2022) Kuo Jiang et al.   Cell Death Discovery

Development of a novel PROTAC using the nucleic acid aptamer as a targeting ligand for tumor selective degradation of nucleolin

(2022) Lin Zhang et al.   Molecular Therapy-Nucleic Acids

Breast cancer

(2021) Sibylle Loibl et al.   LANCET

Advances in targeting ‘undruggable’ transcription factors with small molecules

(2021) Matthew J. Henley et al.   NATURE REVIEWS DRUG DISCOVERY

TF-PROTACs Enable Targeted Degradation of Transcription Factors

(2021) Jing Liu et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

A Threose Nucleic Acid Enzyme with RNA Ligase Activity

(2021) Yao Wang et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

The MYC oncogene — the grand orchestrator of cancer growth and immune evasion

(2021) Renumathy Dhanasekaran et al.   Nature Reviews Clinical Oncology

Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG

(2021) Jingwei Shao et al.   Advanced Science

Cationic Liposomes as Vectors for Nucleic Acid and Hydrophobic Drug Therapeutics

(2021) Kai K. Ewert et al.   Pharmaceutics

An RNA-cleaving threose nucleic acid enzyme capable of single point mutation discrimination

(2021) Yueyao Wang et al.   Nature Chemistry

Transliteration of synthetic genetic enzymes

(2021) Yajun Wang et al.   NUCLEIC ACIDS RESEARCH

Generating Biologically Stable TNA Aptamers that Function with High Affinity and Thermal Stability

(2020) Matthew R. Dunn et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

SOX9 interacts with FOXC1 to activate MYC and regulate CDK7 inhibitor sensitivity in triple-negative breast cancer

(2020) Lin Tang et al.   Oncogenesis

c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis

(2020) Wenfei Ji et al.   Cell Death & Disease

RNA‐PROTACs: Degraders of RNA‐Binding Proteins

(2020) Alice Ghidini et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Immunotherapy and targeted therapy combinations in metastatic breast cancer

(2019) Francisco J Esteva et al.   LANCET ONCOLOGY

Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy

(2019) Huiying Han et al.   CANCER CELL

OUP accepted manuscript

(2018)   NUCLEIC ACIDS RESEARCH

Synthetic materials at the forefront of gene delivery

(2018) Irene Lostalé-Seijo et al.   Nature Reviews Chemistry

De novo MYC addiction as an adaptive response of cancer cells to CDK4/6 inhibition

(2017) Míriam Tarrado‐Castellarnau et al.   Molecular Systems Biology

Improving Polymerase Activity with Unnatural Substrates by Sampling Mutations in Homologous Protein Architectures

(2016) Matthew R. Dunn et al.   ACS Chemical Biology

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

(2016) Shaokun Shu et al.   NATURE

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

(2016) Giampaolo Bianchini et al.   Nature Reviews Clinical Oncology

MYC regulates the antitumor immune response through CD47 and PD-L1

(2016) S. C. Casey et al.   SCIENCE

Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines

(2015) Mikhail O Durymanov et al.   Theranostics

Inhibitor of MYC identified in a Krohnke pyridine library

(2014) J. R. Hart et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genome Recognition by MYC

(2014) A. Sabo et al.   Cold Spring Harbor Perspectives in Medicine

MYC on the Path to Cancer

(2012) Chi V. Dang   CELL

Darwinian evolution of an alternative genetic system provides support for TNA as an RNA progenitor

(2012) Hanyang Yu et al.   Nature Chemistry

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Modelling Myc inhibition as a cancer therapy

(2008) Laura Soucek et al.   NATURE